https://orcid.org/0000-0002-3340-1287
Overview
cancer pharmacogenomics
drug induced neuropathy, neutropenia and hypertension
statistical genetics
statistical methods for high-dimensional data
copulas
survival analysis
statistical computing
drug induced neuropathy, neutropenia and hypertension
statistical genetics
statistical methods for high-dimensional data
copulas
survival analysis
statistical computing
Current Duke Appointments & Affiliations
Professor of Biostatistics & Bioinformatics
·
2021 - Present
Biostatistics & Bioinformatics, Division of Integrative Genomics,
Biostatistics & Bioinformatics
Director, DCI Bioinformatics
·
2013 - Present
Biostatistics & Bioinformatics, Division of Biostatistics,
Biostatistics & Bioinformatics
Member of the Duke Cancer Institute
·
2013 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Scholarly Works
Atezolizumab in combination with neoadjuvant chemotherapy and interval cytoreductive surgery for patients with newly diagnosed advanced-stage epithelial ovarian cancer: the AdORN study.
Journal article Gynecol Oncol · July 2026 OBJECTIVE: Evaluate safety, efficacy, and response markers to atezolizumab, an immune checkpoint inhibitor, when combined with neoadjuvant chemotherapy (NACT) for primary epithelial ovarian, tubal, and peritoneal cancer (EOC). METHODS: Eligible patients ha ... Full text Link to item CiteAlirocumab plus cemiplimab in immuno-refractory metastatic NSCLC: A single-arm, multi-center, phase 2 study.
Conference Journal of Clinical Oncology · June 1, 2026 2619Background: Immunotherapy resistance remains a significant unmet clinical need for most non-small cell lung cancer (NSCLC) patients. PCSK9 was shown in preclinical models to mediate cancer immunotherapy resistance and may serve as a novel immuno-inhibi ... Full text CiteSpatial proteomics of breast ductal carcinoma in situ reveal distinct regional differences.
Journal article Sci Rep · March 13, 2026 Breast ductal carcinoma in situ is a common non-invasive clinical finding that can progress to invasive breast cancer (IBC). Spatial proteomics can provide an additional dimension to our understanding of this disease and its capacity to progress. A subset ... Full text Link to item CiteRecent Grants
A Multiscale Approach to Defining High-Risk Lesions and Neighborhoods for Breast Precancers
ResearchCo Investigator · Awarded by National Institutes of Health · 2026 - 2031Pathological B Cells: Novel Strategies to Prevent and Treat Chronic GVHD
ResearchCo Investigator · Awarded by National Institutes of Health · 2015 - 2031Comparing an Operation to Monitoring, with or without Endocrine Therapy (COMET), for low-risk DCIS - clinical follow-up
ResearchBiostatistician · Awarded by Department of Defense · 2026 - 2030View All Grants
Education
University of North Carolina, Chapel Hill ·
2002
Ph.D.